Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.

Goal 2: Reduce Human Disease

Will Novel Therapies Create Bleeding Remission HHT and Angiogenic Disorders

Chronic bleeding due to epistaxis and gastrointestinal bleeding telangiectasia in HHT leads to transfusion dependence, iron infusion dependence,

decreased quality of life and premature death.

 

Novel therapies such as pomolidamide, Avastin and pazopanib may be new promising therapies to lead to remission in bleeding and reduce the burden of disease

Submitted by (@mariannes.clancy)

Voting

1 net vote
2 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Pathobiology of Lung Fibrosis

End organ fibrosis accounts for up to 45% of deaths in developed countries. In particular, lung fibrosis is a devastating disease with poor prognosis. Despite development of two new drugs, their efficacy is still limited, highlighting the need to better understand the pathobiology that accounts for fibrotic disease progression in the presence and absence of acute exacerbation or infectious drivers.

Submitted by (@bmoore)

Voting

19 net votes
30 up votes
11 down votes
Active

Goal 2: Reduce Human Disease

How can we increase the pharmaceutical clinical research of targeted therapies in pediatric PAH patients, including encouraging

Clinical research, especially randomized pharmaceutical clinical trials, poses many unique challenges compared to research in adult subjects. In pulmonary arterial hypertension, a disease characterized by high blood pressure of the lungs with increased pulmonary vascular resistance leading to right ventricular failure, there are 12 FDA-approved PAH-targeted therapies for adults. None of these medications are currently ...more »

Submitted by (@katherinek)

Voting

66 net votes
76 up votes
10 down votes
Active

Goal 2: Reduce Human Disease

Molecular mechanism for hypertension and the diverse co-morbidities

What molecular mechanism causes hypertension as well as the diverse co-morbidities in hypertension? We discovered a fundamental mechanism that causes chronic and acute tissue injury due to the action of the powerful digestive enzymes, the same used for daily digestion. In various acute and chronic cardiovascular conditions the compartmentalization of these enzymes fails and they escape into the intestine and systemic ...more »

Submitted by (@gwss00)

Voting

-1 net votes
2 up votes
3 down votes
Active

Goal 2: Reduce Human Disease

Targeting Inflammation in Venous Thromboembolism

What is the role of inflamation in venous thromboembolism, both DVT and PE. If the inflammatory response can be controlled, then clot formation should be able to be decreased or eliminated without bleeding potential. The effect of the inflammatory response on the wall of the veins, both in the legs and the lungs, leads to changes that result in pain and swelling (legs) and pulmonary artery hypertension (lungs). Inhibiting ...more »

Submitted by (@thomasww)

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 2: Reduce Human Disease

Physical Activity and Sedentary Behavior Research

There is a need to enhance research efficiency for physical activity and sedentary behavior research by facilitating standardization of the definition of sedentary behavior; employing research strategies that support reliable, valid, and efficient ways to measure and analyze sedentary behaviors; supporting better approaches for data harmonization to promote comparability across studies; and facilitating the use of platforms ...more »

Submitted by (@nhlbiforumadministrator1)

Voting

44 net votes
75 up votes
31 down votes
Active

Goal 2: Reduce Human Disease

New ideas from drug-induced cardiotoxicity

What are the fundamental mechanisms of drug, chemical, or biologics-induced cardiotoxicity (e.g., which proteins or signaling targets are most vulnerable)? Would such knowledge lead to understanding of the most critical signaling systems and contribute to development of new therapeutic (cardioprotective) strategies?

Submitted by (@nhlbiforumadministrator1)

Voting

19 net votes
45 up votes
26 down votes
Active